1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models.

          Methods

          H19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects.

          Results

          H19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs.

          Conclusions

          Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12935-024-03231-6.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates

            Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression.

              lncRNA H19 is essential for human tumor growth. However, little is known about whether H19 regulates bladder cancer metastasis. Here we found that H19 levels are remarkably increased in bladder cancer tissues, and upregulated H19 promotes bladder cancer cell migration in vitro and in vivo. H19 is associated with enhancer of zeste homolog 2 (EZH2), and that this association results in Wnt/β-catenin activation and subsequent downregulation of E-cadherin. A significant negative correlation is also observed between H19 levels and E-cad levels in vivo. These data suggest that upregulated H19 enhances bladder cancer metastasis by associating with EZH2 and inhibiting E-cad expression. Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                antonella.farsetti@cnr.it
                simona.nanni@unicatt.it
                Journal
                Cancer Cell Int
                Cancer Cell Int
                Cancer Cell International
                BioMed Central (London )
                1475-2867
                5 February 2024
                5 February 2024
                2024
                : 24
                : 56
                Affiliations
                [1 ]Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, ( https://ror.org/03h7r5v07) Largo F. Vito 1, Rome, 00168 Italy
                [2 ]GRID grid.5326.2, ISNI 0000 0001 1940 4177, National Research Council (CNR)-IASI, ; Rome, Italy
                [3 ]GRID grid.411075.6, ISNI 0000 0004 1760 4193, Fondazione “Policlinico Universitario A. Gemelli IRCCS”, ; Rome, Italy
                [4 ]Department of Neuroscience, Università Cattolica del Sacro Cuore, ( https://ror.org/03h7r5v07) Rome, Italy
                [5 ]Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, ( https://ror.org/02be6w209) Rome, Italy
                [6 ]Department of Woman, Child and Public Health, Università Cattolica del Sacro Cuore, ( https://ror.org/03h7r5v07) Rome, Italy
                [7 ]GRID grid.417520.5, ISNI 0000 0004 1760 5276, Translational Oncology Research Unit, , IRCCS- Regina Elena National Cancer Institute, ; Rome, Italy
                [8 ]Laboratory of Epigenetics, Istituti Clinici Scientifici Maugeri IRCCS, ( https://ror.org/00mc77d93) Pavia, Italy
                [9 ]GRID grid.412311.4, Department of Medical Physics, S. Orsola, , Malpighi University Hospital, ; Bologna, Italy
                Article
                3231
                10.1186/s12935-024-03231-6
                10845766
                38317193
                7ed849f5-5154-4163-b2c1-4d5e9190291a
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 4 September 2023
                : 18 January 2024
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100009880, Regione Lazio;
                Award ID: project ID A0375-2020-36597
                Funded by: FundRef http://dx.doi.org/10.13039/501100021856, Ministero dell’Università e della Ricerca;
                Award ID: FISR2019_00374
                Funded by: Ricerca Corrente
                Award ID: Progetto di Rete Aging “Promising” Ricerca Corrente 2021
                Funded by: EU-CardioRNA COST Action
                Award ID: CA17129
                Funded by: FundRef http://dx.doi.org/10.13039/501100009882, Regione Lombardia;
                Award ID: progetto “Immunhub”
                Funded by: FundRef http://dx.doi.org/10.13039/501100003196, Ministero della Salute;
                Award ID: RF-2019-12370266
                Funded by: FundRef http://dx.doi.org/10.13039/501100003407, Ministero dell’Istruzione, dell’Università e della Ricerca;
                Award ID: PRIN2017S55RXB
                Funded by: FundRef http://dx.doi.org/10.13039/100020581, Fondazione AIRC per la ricerca sul cancro ETS;
                Award ID: AIRC under IG 2019-ID 22858 project—PI Nanni Simona
                Categories
                Research
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2024

                Oncology & Radiotherapy
                lncrna,metastasis,lysine demethylase,preclinical models
                Oncology & Radiotherapy
                lncrna, metastasis, lysine demethylase, preclinical models

                Comments

                Comment on this article